Search results
Results from the WOW.Com Content Network
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and T-type calcium channels , which leads to the suppression of neuronal hypersynchronization ...
l-DOPA can be manufactured and in its pure form is sold as a drug with the INN Tooltip International Nonproprietary Name levodopa. Trade names include Sinemet, Pharmacopa, Atamet, and Stalevo. As a drug, it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia. l-DOPA has a counterpart with opposite chirality ...
The drug is a centrally permeable monoamine precursor and prodrug of dopamine and hence acts as a dopamine receptor agonist. [3] Chemically, levodopa is an amino acid, a phenethylamine, and a catecholamine. [3] Levodopa was first synthesized and isolated in the early 1910s. [3] The antiparkinsonian effects of levodopa were discovered in the ...
DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue that can serve as a levodopa and dopamine prodrug and is of potential interest in the treatment of Parkinson's disease. [ 1 ] [ 2 ] [ 3 ] DopAmide has an amide rather than the carboxyl group of L -DOPA, [ 2 ] [ 3 ] which imparts greater water solubility .
Generally, drugs outlined within the ATC code N04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiparkinsonian agents .
Carbidopa also helps prevent some of the nausea which levodopa causes. [11] It is on the World Health Organization's List of Essential Medicines. [12] It is available as a generic medication. [10] In 2022, it was the 278th most commonly prescribed medication in the United States, with more than 700,000 prescriptions. [13] [14]
Data from studies conducted on women taking antiepileptic drugs for non-epileptic reasons, including depression and bipolar disorder, show that if high doses of the drugs are taken during the first trimester of pregnancy then there is the potential of an increased risk of congenital malformations.
An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, extracerebral decarboxylase inhibitor, DDCI and AAADI) is a medication of type enzyme inhibitor which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC, AAAD, or DOPA decarboxylase).